<DOC>
	<DOCNO>NCT00509184</DOCNO>
	<brief_summary>Combination involve field radiotherapy control macroscopic disease CD20 antibody Rituximab control microscopic remainder region patient early stage nodal follicular lymphoma /grade I II ) . Evaluation DFSl toxicity .</brief_summary>
	<brief_title>Rituximab Involved Field Radiotherapy Early Stage Follicular Lymphoma</brief_title>
	<detailed_description>The MIR ( Mabthera ( R ) Involved field Radiation ) study prospective multicenter trial combine systemic treatment anti CD20 antibody Rituximab ( Mabthera ( R ) ) combination involve field radiotherapy ( 30 - 40 Gy ) . This trial aim test combination 's efficacy safety accrual 85 patients.Primary endpoint study progression free survival . Secondary endpoint response rate Rituximab , complete remission rate week 18 , relapse rate , relapse pattern , relapse free survival , overall survival , toxicity quality life . More detail : Witzens-Harig M , Hensel M , Unterhalt M , Herfarth K. Treatment limit stage follicular lymphoma Rituximab immunotherapy involve field radiotherapy prospective multicenter Phase II trial-MIR trial . BMC cancer . 2011 ; 11 : 87 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>verified follicular lymphoma grade 1 2 nodal involvement ( incl . Waldeyer ) clinical stage I II large tumor â‰¤ 7 cm adequate bone marrow reserve ECOG &gt; 2 Follicular lymphoma grade 3 buky disease ( &gt; 7 cm ) involvement spleen neoplasia PMH ( except : basalioma , spinalioma ) Immunodeficiency syndromes , viral hepatitis , connective tissue disease severe psychiatric disease pregnancy breast feed known allergy foreign protein</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>untreated</keyword>
</DOC>